What I like about it...
- Price has cleared a significant Volume by Price
- Volume is constructive over the last 10 days...but more volume needs to come in to push it forward
- It is solvent (but not profitable) and has already had a recent public offering.
- Revenues are growing
- It's a biotech and subject to the vagaries of all biotechs.
- It is not profitable, so there is a cash burn.